Literature DB >> 20620674

Macrophages and renal fibrosis.

Madeleine A Vernon1, Katie J Mylonas, Jeremy Hughes.   

Abstract

Renal fibrosis is a key determinant of the progression of renal disease irrespective of the original cause and thus can be regarded as a final common pathway that dictates eventual outcome. The development of renal fibrosis involves many cellular and molecular mediators including leukocytes, myofibroblasts, cytokines, and growth factors, as well as metalloproteinases and their endogenous inhibitors. Study of experimental and human renal disease has shown the involvement of macrophages in renal fibrosis resulting from diverse disease processes. Recent work exploring the nature of both circulating monocytes and tissue macrophages has highlighted their multifaceted phenotype and this impacts their role in renal fibrosis in vivo. In this review we outline the key players in the fibrotic response of the injured kidney and discuss the role of monocytes and macrophages in renal scarring.

Entities:  

Mesh:

Year:  2010        PMID: 20620674     DOI: 10.1016/j.semnephrol.2010.03.004

Source DB:  PubMed          Journal:  Semin Nephrol        ISSN: 0270-9295            Impact factor:   5.299


  55 in total

Review 1.  The renal mononuclear phagocytic system.

Authors:  Peter J Nelson; Andrew J Rees; Matthew D Griffin; Jeremy Hughes; Christian Kurts; Jeremy Duffield
Journal:  J Am Soc Nephrol       Date:  2011-12-01       Impact factor: 10.121

Review 2.  Cellular and molecular mechanisms of renal fibrosis.

Authors:  Youhua Liu
Journal:  Nat Rev Nephrol       Date:  2011-10-18       Impact factor: 28.314

Review 3.  Anti-fibrosis therapy and diabetic nephropathy.

Authors:  Anil Karihaloo
Journal:  Curr Diab Rep       Date:  2012-08       Impact factor: 4.810

4.  Macrophage dynamics in AKI to CKD progression.

Authors:  Gilbert R Kinsey
Journal:  J Am Soc Nephrol       Date:  2013-12-05       Impact factor: 10.121

5.  FXR/TGR5 Dual Agonist Prevents Progression of Nephropathy in Diabetes and Obesity.

Authors:  Xiaoxin X Wang; Dong Wang; Yuhuan Luo; Komuraiah Myakala; Evgenia Dobrinskikh; Avi Z Rosenberg; Jonathan Levi; Jeffrey B Kopp; Amanda Field; Ashley Hill; Scott Lucia; Liru Qiu; Tao Jiang; Yingqiong Peng; David Orlicky; Gabriel Garcia; Michal Herman-Edelstein; Vivette D'Agati; Kammi Henriksen; Luciano Adorini; Mark Pruzanski; Cen Xie; Kristopher W Krausz; Frank J Gonzalez; Suman Ranjit; Alexander Dvornikov; Enrico Gratton; Moshe Levi
Journal:  J Am Soc Nephrol       Date:  2017-10-31       Impact factor: 10.121

Review 6.  Inflammatory processes in renal fibrosis.

Authors:  Xiao-Ming Meng; David J Nikolic-Paterson; Hui Yao Lan
Journal:  Nat Rev Nephrol       Date:  2014-07-01       Impact factor: 28.314

Review 7.  Renal interstitial fibrosis: mechanisms and evaluation.

Authors:  Alton B Farris; Robert B Colvin
Journal:  Curr Opin Nephrol Hypertens       Date:  2012-05       Impact factor: 2.894

8.  The aldosterone receptor antagonist spironolactone prevents peritoneal inflammation and fibrosis.

Authors:  Lei Zhang; Jian-Bing Hao; Lian-Sheng Ren; Jiu-Li Ding; Li-Rong Hao
Journal:  Lab Invest       Date:  2014-05-26       Impact factor: 5.662

Review 9.  TGF-β signaling in tissue fibrosis: redox controls, target genes and therapeutic opportunities.

Authors:  Rohan Samarakoon; Jessica M Overstreet; Paul J Higgins
Journal:  Cell Signal       Date:  2012-10-11       Impact factor: 4.315

Review 10.  Can we target tubular damage to prevent renal function decline in diabetes?

Authors:  Joseph V Bonventre
Journal:  Semin Nephrol       Date:  2012-09       Impact factor: 5.299

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.